Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05986292 | A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain | PHASE2 | RECRUITING | 10,000 | — | — | Jan 30, 2020 | Apr 1, 2027 | Apr 20, 2026 | 64 | United States, Puerto Rico |
| Arm | Type | Description |
|---|---|---|
| LY3016859 Osteoarthritis ISA | EXPERIMENTAL | Participants are randomized to receive either active LY3016859 or matching placebo |
| LY3016859 Diabetic Neuropathic Pain ISA | EXPERIMENTAL | Participants are randomized to receive either active LY3016859 or matching placebo |
| LY3016859 Chronic Back Pain ISA | EXPERIMENTAL | Participants are randomized to receive either active LY3016859 or matching placebo |
| LY3556050 Osteoarthritis ISA | EXPERIMENTAL | Participants are randomized to receive either active LY3556050 or matching placebo |
| LY3556050 Diabetic Neuropathic Pain ISA | EXPERIMENTAL | Participants are randomized to receive either active LY3556050 or matching placebo |
| LY3556050 Chronic Back Pain ISA | EXPERIMENTAL | Participants are randomized to receive either active LY3556050 or matching placebo |
| LY3526318 Osteoarthritis ISA | EXPERIMENTAL | Participants are randomized to receive either active LY3526318 or matching placebo |
| LY3526318 Diabetic Neuropathic Pain ISA | EXPERIMENTAL | Participants are randomized to receive either active LY3526318 or matching placebo |
| LY3526318 Chronic Back Pain ISA | EXPERIMENTAL | Participants are randomized to receive either active LY3526318 or matching placebo |
| LY3857210 Osteoarthritis ISA | EXPERIMENTAL | Participants are randomized to receive either active LY3857210 or matching placebo |
| LY3857210 Diabetic Neuropathic Pain ISA | EXPERIMENTAL | Participants are randomized to receive either active LY3857210 or matching placebo |
| LY3857210 Chronic Back Pain ISA | EXPERIMENTAL | Participants are randomized to receive either active LY3857210 or matching placebo |
| Name | Type | Description |
|---|---|---|
| LY3016859 ISA | DRUG | Administered intravenously (IV) |
| LY3556050 ISA | DRUG | Administered orally |
| LY3526318 ISA | DRUG | Administered orally |
| LY3857210 ISA | DRUG | Administered orally |
| Placebo Oral | DRUG | Placebo administered orally |
| Placebo | DRUG | Placebo administered IV |
Inclusion Criteria: * have a visual analog scale (VAS) pain value \>40 and \<95 at screening and prerandomization screening. * have a history of daily pain for at least 12 weeks based on participant report or medical history * have a value of ≤30 on the pain catastrophizing scale * have a body mass...